These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

683 related articles for article (PubMed ID: 19125126)

  • 21. Screening for germline mutations of MLH1, MSH2, MSH6 and PMS2 genes in Slovenian colorectal cancer patients: implications for a population specific detection strategy of Lynch syndrome.
    Berginc G; Bracko M; Ravnik-Glavac M; Glavac D
    Fam Cancer; 2009; 8(4):421-9. PubMed ID: 19526325
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Microsatellite instability and colorectal cancer.
    Geiersbach KB; Samowitz WS
    Arch Pathol Lab Med; 2011 Oct; 135(10):1269-77. PubMed ID: 21970482
    [TBL] [Abstract][Full Text] [Related]  

  • 23. One to 2-year surveillance intervals reduce risk of colorectal cancer in families with Lynch syndrome.
    Vasen HF; Abdirahman M; Brohet R; Langers AM; Kleibeuker JH; van Kouwen M; Koornstra JJ; Boot H; Cats A; Dekker E; Sanduleanu S; Poley JW; Hardwick JC; de Vos Tot Nederveen Cappel WH; van der Meulen-de Jong AE; Tan TG; Jacobs MA; Mohamed FL; de Boer SY; van de Meeberg PC; Verhulst ML; Salemans JM; van Bentem N; Westerveld BD; Vecht J; Nagengast FM
    Gastroenterology; 2010 Jun; 138(7):2300-6. PubMed ID: 20206180
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular testing for Lynch syndrome in people with colorectal cancer: systematic reviews and economic evaluation.
    Snowsill T; Coelho H; Huxley N; Jones-Hughes T; Briscoe S; Frayling IM; Hyde C
    Health Technol Assess; 2017 Sep; 21(51):1-238. PubMed ID: 28895526
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficient molecular screening of Lynch syndrome by specific 3' promoter methylation of the MLH1 or BRAF mutation in colorectal cancer with high-frequency microsatellite instability.
    Nakagawa H; Nagasaka T; Cullings HM; Notohara K; Hoshijima N; Young J; Lynch HT; Tanaka N; Matsubara N
    Oncol Rep; 2009 Jun; 21(6):1577-83. PubMed ID: 19424639
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The identification of Lynch syndrome in British Columbia.
    Cremin CM; Armstrong L; Gill S; Huntsman D; Bajdik C
    Can J Gastroenterol; 2009 Nov; 23(11):761-7. PubMed ID: 19893772
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lower cancer incidence in Amsterdam-I criteria families without mismatch repair deficiency: familial colorectal cancer type X.
    Lindor NM; Rabe K; Petersen GM; Haile R; Casey G; Baron J; Gallinger S; Bapat B; Aronson M; Hopper J; Jass J; LeMarchand L; Grove J; Potter J; Newcomb P; Terdiman JP; Conrad P; Moslein G; Goldberg R; Ziogas A; Anton-Culver H; de Andrade M; Siegmund K; Thibodeau SN; Boardman LA; Seminara D
    JAMA; 2005 Apr; 293(16):1979-85. PubMed ID: 15855431
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A prospective, multicenter, population-based study of BRAF mutational analysis for Lynch syndrome screening.
    Bessa X; Ballesté B; Andreu M; Castells A; Bellosillo B; Balaguer F; Castellví-Bel S; Paya A; Jover R; Alenda C; Titó L; Martinez-Villacampa M; Vilella A; Xicola RM; Pons E; Llor X;
    Clin Gastroenterol Hepatol; 2008 Feb; 6(2):206-14. PubMed ID: 18096441
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assessment of Tumor Sequencing as a Replacement for Lynch Syndrome Screening and Current Molecular Tests for Patients With Colorectal Cancer.
    Hampel H; Pearlman R; Beightol M; Zhao W; Jones D; Frankel WL; Goodfellow PJ; Yilmaz A; Miller K; Bacher J; Jacobson A; Paskett E; Shields PG; Goldberg RM; de la Chapelle A; Shirts BH; Pritchard CC;
    JAMA Oncol; 2018 Jun; 4(6):806-813. PubMed ID: 29596542
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevalence of mismatch repair-deficient crypt foci in Lynch syndrome: a pathological study.
    Kloor M; Huth C; Voigt AY; Benner A; Schirmacher P; von Knebel Doeberitz M; Bläker H
    Lancet Oncol; 2012 Jun; 13(6):598-606. PubMed ID: 22552011
    [TBL] [Abstract][Full Text] [Related]  

  • 31. BRAF V600E-specific immunohistochemistry for the exclusion of Lynch syndrome in MSI-H colorectal cancer.
    Capper D; Voigt A; Bozukova G; Ahadova A; Kickingereder P; von Deimling A; von Knebel Doeberitz M; Kloor M
    Int J Cancer; 2013 Oct; 133(7):1624-30. PubMed ID: 23553055
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Feasibility of screening for Lynch syndrome among patients with colorectal cancer.
    Hampel H; Frankel WL; Martin E; Arnold M; Khanduja K; Kuebler P; Clendenning M; Sotamaa K; Prior T; Westman JA; Panescu J; Fix D; Lockman J; LaJeunesse J; Comeras I; de la Chapelle A
    J Clin Oncol; 2008 Dec; 26(35):5783-8. PubMed ID: 18809606
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness analysis of genetic diagnostic strategies for Lynch syndrome in Italy.
    Pastorino R; Basile M; Tognetto A; Di Marco M; Grossi A; Lucci-Cordisco E; Scaldaferri F; De Censi A; Federici A; Villari P; Genuardi M; Ricciardi W; Boccia S
    PLoS One; 2020; 15(7):e0235038. PubMed ID: 32609729
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer).
    Hampel H; Frankel WL; Martin E; Arnold M; Khanduja K; Kuebler P; Nakagawa H; Sotamaa K; Prior TW; Westman J; Panescu J; Fix D; Lockman J; Comeras I; de la Chapelle A
    N Engl J Med; 2005 May; 352(18):1851-60. PubMed ID: 15872200
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hereditary nonpolyposis colorectal cancer: diagnostic strategies and their implications.
    Bonis PA; Trikalinos TA; Chung M; Chew P; Ip S; DeVine DA; Lau J
    Evid Rep Technol Assess (Full Rep); 2007 May; (150):1-180. PubMed ID: 17764220
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recommendations from the EGAPP Working Group: can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan?
    Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group
    Genet Med; 2009 Jan; 11(1):15-20. PubMed ID: 19125128
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Taiwan hospital-based detection of Lynch syndrome distinguishes 2 types of microsatellite instabilities in colorectal cancers.
    Chang SC; Lin PC; Yang SH; Wang HS; Liang WY; Lin JK
    Surgery; 2010 May; 147(5):720-8. PubMed ID: 20045164
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of selection strategies for genetic testing of patients with hereditary nonpolyposis colorectal carcinoma: effectiveness and cost-effectiveness.
    Reyes CM; Allen BA; Terdiman JP; Wilson LS
    Cancer; 2002 Nov; 95(9):1848-56. PubMed ID: 12404277
    [TBL] [Abstract][Full Text] [Related]  

  • 39. BRAF mutation analysis is a valid tool to implement in Lynch syndrome diagnosis in patients classified according to the Bethesda guidelines.
    Molinari F; Signoroni S; Lampis A; Bertan C; Perrone F; Sala P; Mondini P; Crippa S; Bertario L; Frattini M
    Tumori; 2014; 100(3):315-20. PubMed ID: 25076244
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A review on the molecular diagnostics of Lynch syndrome: a central role for the pathology laboratory.
    van Lier MG; Wagner A; van Leerdam ME; Biermann K; Kuipers EJ; Steyerberg EW; Dubbink HJ; Dinjens WN
    J Cell Mol Med; 2010 Jan; 14(1-2):181-97. PubMed ID: 19929944
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.